# Registries count diagnoses and deaths, and not what treatment left behind

Source: https://onco.cc/bottlenecks/rejuv-agenda-late-effects-are-not-counted/  
OnCo record `rejuv-agenda-late-effects-are-not-counted` (Bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cancer registries are good at incidence and mortality and record almost nothing about late effects, so the scale of the problem is estimated from a handful of cohorts rather than counted. Europe cannot say how many survivors it has.

## Summary

Almost everything this front knows about what treatment leaves behind comes from a small number of cohorts, most of them in childhood cancer, most of them North American, and most of them describing treatment given decades ago. The Childhood Cancer Survivor Study, the St Jude Lifetime Cohort, the British Childhood Cancer Survivor Study and the PanCare consortium carry a disproportionate share of the evidence on this entire front. They are excellent and they are not a surveillance system.

The consequences show up as honest refusals throughout this round's records. For Europe, the survivor-cohort record quotes a 2024 scoping review finding that information on prevalence is fragmented and inconsistent, and states that nobody knows accurately how many European survivors there are to plan services for. For adults, there is no cohort of comparable depth at all, and the frailty record says plainly that the childhood cohorts are mostly childhood cancer and mostly White, so they do not transfer to adults or to other populations. For newer treatments there is nothing: mortality after immunotherapy and cell therapy in children has no long-term cohort yet. For skin cancer after treatment, any figure for how many survivors develop one is an undercount because of how such cancers are recorded.

The mechanism of the gap is simple. Registries were built to measure whether a population's cancer incidence and mortality are changing, which is the question public health asked of them, and they do it well. Morbidity after treatment was never in their remit, has no reporting pathway, and appears years later in a different service that does not know the registry exists. Late effects are therefore invisible in the official statistics of every country, which is why they are chronically under-resourced: the number that would justify the budget has never been produced.

This is the bottleneck under several of the others. A screening programme cannot be designed without risk estimates; a service cannot be commissioned for a population of unknown size; a trial cannot be powered on a prevalence nobody has measured.

## Fields

- Kind: Bottleneck
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; open-problem; registries; data
- Stage: data-knowledge
- Severity: critical
- Metrics: Childhood Cancer Survivor Study: eligible five-year survivors identified, and participants completing the baseline questionnaire: 20,276 eligible from 25 institutions; 14,054 participants (Robison et al., Medical and Pediatric Oncology 2002); European prevalence of childhood cancer survivors: "Information on prevalence of CCS in Europe is fragmented and inconsistent." (2024 scoping review, quoted on the PanCareSurFup record); Cancer registries that routinely record late effects of treatment: None found by OnCo (OnCo, 2 October 2026)
- Causes: Registries were designed to measure incidence and mortality, and late morbidity was never in their remit or their funding.; Late effects appear years after treatment, in a different service, which has no route to report them back.; There is no standard coding for a late effect of treatment that distinguishes it from the same condition arising ordinarily.; Cohorts that do measure it are research-funded, so they follow the populations the grants cover and stop when the grants do.; Adults, who are the overwhelming majority of survivors, have no cohort with the exposure detail the paediatric cohorts have.

## Sources

- Robison et al., Study design and cohort characteristics of the Childhood Cancer Survivor Study (Medical and Pediatric Oncology 2002;38:229-239): https://doi.org/10.1002/mpo.1316
- NCI Office of Cancer Survivorship: statistics and graphs: https://cancercontrol.cancer.gov/ocs/statistics
- Hudson et al., Clinical ascertainment of health outcomes among adults treated for childhood cancer (JAMA 2013;309:2371): https://doi.org/10.1001/jama.2013.6296

## Connected records

- trials: [Childhood Cancer Survivor Study (CCSS)](https://onco.cc/trials/ccss/)
- collections: [British Childhood Cancer Survivor Study (BCCSS)](https://onco.cc/collections/bccss/), [International Guideline Harmonization Group for late effects of childhood cancer](https://onco.cc/collections/ighg/), [PanCareSurFup and the European survivor cohorts](https://onco.cc/collections/pancaresurfup/), [SEER (Surveillance, Epidemiology, and End Results)](https://onco.cc/collections/seer/), [St Jude Lifetime Cohort Study (SJLIFE)](https://onco.cc/collections/sjlife/)
- technologies: [Frailty and late effects in survivors](https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/), [How much illness childhood cancer survivors carry, and at what age](https://onco.cc/technologies/rejuv-paed-chronic-disease-burden/), [Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked](https://onco.cc/technologies/rejuv-paed-late-mortality/)
- terms: [Counting the people who live after cancer, and why the number is not a detail](https://onco.cc/terms/rejuv-history-counting-survivors/), [Cure is not enough: when late effects stopped being an afterthought](https://onco.cc/terms/rejuv-history-cure-is-not-enough/)
- ideas: [A lifelong late-effects registry linked to every treatment for adult survivors](https://onco.cc/ideas/idea-moon-adult-late-effects-registry/), [A national late-effects registry linking treatment exposures to outcomes decades later](https://onco.cc/ideas/idea-acc-national-late-effects-registry/), [Ask whether survivorship screening saves lives, using registry-based randomisation](https://onco.cc/ideas/idea-rejuv-registry-randomised-screening-in-survivors/), [Enrol every new systemic therapy into a registry linkage that will still report in thirty years](https://onco.cc/ideas/idea-rejuv-second-cancer-latency-cohort-for-new-drugs/), [Make the treatment exposure record machine-readable, so surveillance can be computed](https://onco.cc/ideas/idea-rejuv-exposure-record-a-machine-can-read/)
- roadmaps: [Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it](https://onco.cc/roadmaps/rejuvenation-roadmap/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- bottlenecks: [The newest treatments have not existed long enough for their late effects to appear](https://onco.cc/bottlenecks/rejuv-agenda-latency-outruns-the-evidence/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-agenda-late-effects-are-not-counted.json